1 Bray F , Ferlay J , Soerjomataram I , Siegel R L , Torre L A , Jemal A : Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
2 Okholm C , Mollerup T K, Schultz N A, Strandby R B, Achiam M P: Synchronous and metachronous liver metastases in patients with colorectal cancer. Dan Med J 2018;65:A5524.
3 Tang J T, Chen H R, Wong C C, Liu D B, Li T, Wang X H, et al: DEAD-box helicase 27 promotes colorectal cancer growth and metastasis and predicts poor survival in CRC patients. Oncogene 2018;37:3006-3021.
4 Engstrand J , Nilsson H, Strömberg C, Jonas E, Freedman J: Colorectal cancer liver metastases – a population-based study on incidence, management and survival. BMC Cancer 2018;18:78.
5 Klein C A: Selection and adaptation during metastatic cancer progression. Nature 2013;501:365-72.
6 Au S H, Storey B D, Moore J C, Tang Q, Chen Y L, Javaid S, et al : Clusters of circulating tumor cells traverse capillary-sized vessels. Proc Natl Acad Sci U S A 2016;113:4947-52.
7 Hüsemann Y, Geigl J B, Schubert F, Musiani P, Meyer M, Burghart E, et al: Systemic spread is an early step in breast cancer. Cancer Cell 2008;13:58-68.
8 Bidard F C, Peeters D J, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, et al: Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 2014;15:406-14.
9 Yu M, Bardia A, Wittner B S, Stott S L, Smas M E, Ting D T, et al: Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013;339:580-4.
10 Fischer K R, Durrans A, Lee S, Sheng J, Li F H, Wong S T C, et al: Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 2015;527:472-6.
11 Zheng X F, Carstens J L, Kim J, Scheible M, Kaye J, Sugimoto H,et al: Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 2015;527:525-530.
12 Li J M, Vranken J G Van, Vaites L P, Schweppe D K, Huttlin E L, Etienne C, et al: TMTpro reagents: a set of isobaric labeling mass tags enables simultaneous proteome-wide measurements across 16 samples. Nat Methods 2020;17:399-404.
13 Latonen L, Afyounian E, Jylhä A,Nättinen J, Aapola U, Annala M,et al: Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression. Nat Commun 2018;9:1176.
14 Piazza I, Kochanowski K, Cappelletti V, Fuhrer T, Noor E, Sauer U, et al: A Map of Protein-Metabolite Interactions Reveals Principles of Chemical Communication. Cell 2018;172:358-372.e23.
15 Musa Y R, Boller S, Puchalska M, Grosschedl R, Mittler G: Comprehensive Proteomic Investigation of Ebf1 Heterozygosity in Pro-B Lymphocytes Utilizing Data Independent Acquisition. J Proteome Res 2018;17:76-85.
16 Cortés-Hernández L E, Eslami-S Z, Alix-Panabières C: Circulating tumor cell as the functional aspect of liquid biopsy to understand the metastatic cascade in solid cancer. Mol Aspects Med 2020; 72:100816.
17 Liu X, Li J J, Cadilha B L, Markota A, Voigt C, Huang Z, et al: Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis. Sci Adv 2019; 5: eaav4275.
18 Papadaki M A, Stoupis G, Theodoropoulos P A, Mavroudis D, Georgoulias V, Agelaki S: Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer. Mol Cancer Ther 2019; 18:437-447.
19 Wang W Y, Wan L, Wu S, Yang J, Zhou Y, Liu F, et al: Mesenchymal marker and LGR5 expression levels in circulating tumor cells correlate with colorectal cancer prognosis. Cell Oncol (Dordr) 2018;41:495-504..
20 Genna A, Vanwynsberghe A, Villard A V, Pottier C, Ancel J, Polette M , et al: EMT-Associated Heterogeneity in Circulating Tumor Cells: Sticky Friends on the Road to Metastasis. Cancers (Basel) 2020; 12:1632.
21 Rauniyar N, Peng Gang, Lam T T, Zhao H Y, Mor G, Williams K R : Data-Independent Acquisition and Parallel Reaction Monitoring Mass Spectrometry Identification of Serum Biomarkers for Ovarian Cancer. Biomark Insights 2017;12:1177271917710948.
22 Sanda M, Goldman R: Data Independent Analysis of IgG Glycoforms in Samples of Unfractionated Human Plasma. Anal Chem 2016;88:10118-10125.
23 Rauniyar N: Parallel Reaction Monitoring: A Targeted Experiment Performed Using High Resolution and High Mass Accuracy Mass Spectrometry. Int J Mol Sci 2015;16:28566-81.
24 Lawson D A, Kessenbrock K , Davis R T, Pervolarakis N, Werb Z: Tumour heterogeneity and metastasis at single-cell resolution. Nat Cell Biol 2018;20:1349-1360.
25 Gupta P B, Pastushenko I, Skibinski A, Blanpain C, Kuperwasser C: Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance. Cell Stem Cell 2019;24:65-78.
26 Yang L, Li A T , Lei Q Y, Zhang Y: Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment. J Hematol Oncol 2019;12:125.
27 Lou Y Y, Diao L X, Cuentas E R P, Denning W L, Chen L M, Fan Y H, et al: Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clin Cancer Res 2016;22:3630-42.
28 Mak M P, Tong P, Diao L X, Cardnell R L, Gibbons D L, William W N, et al: A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clin Cancer Res 2016;22:609-20.